These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36090992)

  • 41. The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.
    Naveed H; Elshafeey A; Al-Ali D; Janjua E; Nauman A; Kawas H; Kaul R; Saed Aldien A; Elshazly MB; Zakaria D
    J Clin Pharmacol; 2021 Aug; 61(8):987-1000. PubMed ID: 33635546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry.
    López-Otero D; López-Pais J; Cacho-Antonio CE; Antúnez-Muiños PJ; González-Ferrero T; Pérez-Poza M; Otero-García Ó; Díaz-Fernández B; Bastos-Fernández M; Bouzas-Cruz N; Sanmartín-Pena XC; Varela-Román A; Portela-Romero M; Valdés-Cuadrado L; Pose-Reino A; González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):175-182. PubMed ID: 32600991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
    Strauss MH; Hall AS
    Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
    Savarese G; Benson L; Sundström J; Lund LH
    Eur J Heart Fail; 2021 Mar; 23(3):476-485. PubMed ID: 33222412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
    Gayat E; Hollinger A; Cariou A; Deye N; Vieillard-Baron A; Jaber S; Chousterman BG; Lu Q; Laterre PF; Monnet X; Darmon M; Leone M; Guidet B; Sonneville R; Lefrant JY; Fournier MC; Resche-Rigon M; Mebazaa A; Legrand M;
    Intensive Care Med; 2018 May; 44(5):598-605. PubMed ID: 29766216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
    Khera R; Clark C; Lu Y; Guo Y; Ren S; Truax B; Spatz ES; Murugiah K; Lin Z; Omer SB; Vojta D; Krumholz HM
    J Am Heart Assoc; 2021 Jul; 10(13):e018086. PubMed ID: 33624516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
    Mareev YV; Mareev VY
    Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.
    Carubelli V; Lombardi C; Specchia C; Peveri G; Oriecuia C; Tomasoni D; Di Pasquale M; Inciardi R; Garrafa E; Metra M
    ESC Heart Fail; 2021 Jun; 8(3):1944-1953. PubMed ID: 33660949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study.
    Dublin S; Walker RL; Floyd JS; Shortreed SM; Fuller S; Albertson-Junkans L; Harrington LB; Greenwood-Hickman MA; Green BB; Psaty BM
    Am J Hypertens; 2021 Apr; 34(4):339-347. PubMed ID: 33048112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19.
    Gupta N; Settle L; Brown BR; Armaignac DL; Baram M; Perkins NE; Kaufman M; Melamed RR; Christie AB; Danesh VC; Denson JL; Cheruku SR; Boman K; Bansal V; Kumar VK; Walkey AJ; Domecq JP; Kashyap R; Aston CE;
    Crit Care Med; 2022 Oct; 50(10):e744-e758. PubMed ID: 35894609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients.
    Baslilar S; Saylan B
    Ann Saudi Med; 2021; 41(5):268-273. PubMed ID: 34618609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The characteristics and outcomes of 681 severe cases with COVID-19 in China.
    Chen FF; Zhong M; Liu Y; Zhang Y; Zhang K; Su DZ; Meng X; Zhang Y
    J Crit Care; 2020 Dec; 60():32-37. PubMed ID: 32736197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
    Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
    Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Higher comorbidities and early death in hospitalized African-American patients with Covid-19.
    Gupta R; Agrawal R; Bukhari Z; Jabbar A; Wang D; Diks J; Alshal M; Emechebe DY; Brunicardi FC; Lazar JM; Chamberlain R; Burza A; Haseeb MA
    BMC Infect Dis; 2021 Jan; 21(1):78. PubMed ID: 33461499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease.
    Juneja A; Zia S; Abeysekara A; Shams S; Singh K; Schor J; Deitch J
    Vascul Pharmacol; 2020 Aug; 131():106764. PubMed ID: 32629143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
    Mayyas F; Bataineh W; Jarab A
    Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia.
    Görmez S; Erel Kırışoğlu C; Ekicibaşı ME; Değirmencioğlu A; Paudel A; Akan G; Atalar F; Sarıgüzel N; Pamukçu B
    Turk Kardiyol Dern Ars; 2021 Jun; 49(4):286-292. PubMed ID: 34106062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis.
    Cai XJ; Tay JCK; Kui SL; Tin AS; Tan VH
    Singapore Med J; 2021 Nov; 62(11):563-567. PubMed ID: 33256355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.